FDA Drug Recalls
17,898 recalls, newest first
Class III · Low risk Ongoing Feb 18, 2026
Reason Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual…
Class III · Low risk Ongoing Feb 18, 2026
Reason Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual…
Class II · Moderate risk Ongoing Feb 17, 2026
Reason Defective container; inadequately sealed blister packaging.
Class II · Moderate risk Ongoing Feb 13, 2026
Reason CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before…
Class II · Moderate risk Ongoing Feb 13, 2026
Reason CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before…
Class II · Moderate risk Ongoing Feb 13, 2026
Reason Failed Dissolution Specifications: This recall has been initiated due to an Out of Specification finding in dissolution.
Class III · Low risk Ongoing Feb 12, 2026
Reason Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The…
Class II · Moderate risk Ongoing Feb 10, 2026
Reason Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
Class II · Moderate risk Ongoing Feb 9, 2026
Reason Defective Delivery System: Missing or duplicated needles within the injection kit
Class II · Moderate risk Ongoing Feb 5, 2026
Reason Lack of Assurance of Sterility
Class II · Moderate risk Ongoing Feb 5, 2026
Reason Lack of Assurance of Sterility
Class II · Moderate risk Ongoing Feb 5, 2026
Reason Lack of Assurance of Sterility
Class II · Moderate risk Ongoing Feb 5, 2026
Reason Lack of Assurance of Sterility
Class II · Moderate risk Ongoing Feb 5, 2026
Reason Lack of Assurance of Sterility
Class II · Moderate risk Ongoing Feb 4, 2026
Reason Failed Impurities/Degradation Specifications - OOS impurities result observed during long term stability testing at product expiry (24 months) were…
Class III · Low risk Ongoing Feb 3, 2026
Reason Presence of foreign tablets/capsules: one Pitavastatin tablet 1mg found in bottle of Pitavastatin tablets 2mg
Class II · Moderate risk Ongoing Feb 2, 2026
Reason cGMP deviations
Class II · Moderate risk Ongoing Feb 2, 2026
Reason cGMP deviations
Class II · Moderate risk Ongoing Jan 29, 2026
Reason Failed Dissolution Specifications
Class II · Moderate risk Ongoing Jan 29, 2026
Reason Failed Dissolution Specifications
Class II · Moderate risk Ongoing Jan 29, 2026
Reason Failed Dissolution Specifications
Class II · Moderate risk Ongoing Jan 29, 2026
Reason Failed Dissolution Specifications
Class II · Moderate risk Ongoing Jan 27, 2026
Reason Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.
Class II · Moderate risk Ongoing Jan 26, 2026
Reason Presence of Particulate Matter: Due to production issues
Class II · Moderate risk Ongoing Jan 26, 2026
Reason Presence of Foreign substance - potential presence of metal particulate matter